Fast Track for Insys' nasal epinephrine

Insys Therapeutics Inc. (NASDAQ:INSY) jumped $2.71 (34%) to $10.67 on Aug. 30 after it said FDA granted Fast Track designation to its epinephrine nasal spray to treat anaphylaxis.

A spokesperson for Insys told BioCentury that the company recently held an end-of-Phase II meeting with FDA and that it will discuss next steps with the agency this fall...